# Retatrutide's UK development status

Canonical: https://europeanpeptideshop.com/blog/retatrutide-uk-release-date/

Explore the catalogue and research library. Ordering and shipping have not opened yet.

Research news · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/)

### On this page

Retatrutide in the UK has no licence and no release date. The MHRA said on 15 October 2026: "Retatrutide has not been authorised for use in the UK."

## What has the MHRA said about retatrutide in the UK?

The statement followed a [£2 million raid in Birmingham](https://europeanpeptideshop.com/blog/mhra-birmingham-raid-fake-pens/). The MHRA added that products sold as retatrutide outside legitimate clinical trials were being supplied outside the applicable rules and presented public-health risks.

## Has Lilly filed for retatrutide in the UK?

The sources for this page give no UK date. Lilly's stated plan is for the US. Manufacturing Chemist reported on 24 July 2026 that Lilly planned a US regulatory submission in early 2027. The same report says the data could support global submissions, without giving dates.

## What would a UK licence need?

An application and an MHRA decision. Neither has been reported, and an FDA decision would not cover the UK. The [mechanism page](https://europeanpeptideshop.com/blog/retatrutide-mechanism-of-action/) covers what the molecule is.

Any launch date quoted for retatrutide in the UK is a guess for now.

## Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope.

## Laboratory research only

Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here.

## References

- [MHRA, 15 October 2026](https://www.gov.uk/government/news/counterfeit-weight-loss-pens-worth-2-million-seized-by-mhra-and-west-mids-police)

- [Manufacturing Chemist, 24 July 2026](https://manufacturingchemist.com/eli-lilly-r%65tatrutide-hits-phase-iii-goals-fda)

## More articles

Research news · 3 min read

## [CT-G32 versus retatrutide](https://europeanpeptideshop.com/blog/ct-g32-sco-940-four-pathway-peptide/)

Explore CT-G32/SCO-940’s four-pathway design, the reported rat comparison with retatrutide and what a planned US FDA IND does: and does not: mean.

8 November 2026

Research news · 3 min read

## [Retatrutide and TRIUMPH-4](https://europeanpeptideshop.com/blog/retatrutide-knee-osteoarthritis-triumph-4/)

Understand retatrutide’s TRIUMPH-4 knee-pain results, the placebo comparison, trial population, safety findings and what ACR 2026 adds.

8 November 2026

Research news · 3 min read

## [Retatrutide versus Ozempic: trial data](https://europeanpeptideshop.com/blog/retatrutide-vs-ozempic-transcend-t2d-2/)

Read the October 2026 TRANSCEND-T2D-2 retatrutide versus Ozempic results, study design, outcome estimates and limits of the sponsor announcement.

8 November 2026